BidaskClub downgraded shares of Keryx Biopharmaceuticals (NASDAQ:KERX) from a sell rating to a strong sell rating in a research report released on Thursday.

Several other research analysts have also recently issued reports on the company. HC Wainwright reissued a buy rating and issued a $9.00 price target on shares of Keryx Biopharmaceuticals in a research note on Thursday, August 9th. Zacks Investment Research raised Keryx Biopharmaceuticals from a hold rating to a buy rating and set a $4.50 price target for the company in a research note on Tuesday, July 10th. Maxim Group set a $9.00 price target on Keryx Biopharmaceuticals and gave the stock a buy rating in a research note on Thursday, May 10th. Stifel Nicolaus reissued a hold rating and issued a $5.00 price target on shares of Keryx Biopharmaceuticals in a research note on Monday, June 25th. Finally, ValuEngine raised Keryx Biopharmaceuticals from a sell rating to a hold rating in a research note on Thursday, June 21st. Two analysts have rated the stock with a sell rating, five have assigned a hold rating and one has issued a buy rating to the company. The company currently has a consensus rating of Hold and an average target price of $6.25.

KERX traded up $0.01 during trading on Thursday, reaching $3.02. 47,172 shares of the company were exchanged, compared to its average volume of 1,212,846. The company has a market cap of $395.11 million, a P/E ratio of -3.41 and a beta of 2.59. The company has a debt-to-equity ratio of -3.16, a current ratio of 2.28 and a quick ratio of 1.40. Keryx Biopharmaceuticals has a 52 week low of $2.93 and a 52 week high of $8.07.

Keryx Biopharmaceuticals (NASDAQ:KERX) last issued its quarterly earnings data on Wednesday, August 8th. The biopharmaceutical company reported ($0.18) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.16) by ($0.02). research analysts anticipate that Keryx Biopharmaceuticals will post -0.58 earnings per share for the current year.

Several large investors have recently added to or reduced their stakes in KERX. MetLife Investment Advisors LLC acquired a new stake in shares of Keryx Biopharmaceuticals in the fourth quarter valued at $187,000. Russell Investments Group Ltd. acquired a new stake in shares of Keryx Biopharmaceuticals in the first quarter valued at $201,000. Meridian Wealth Management LLC acquired a new stake in shares of Keryx Biopharmaceuticals in the first quarter valued at $203,000. Mackay Shields LLC acquired a new stake in shares of Keryx Biopharmaceuticals in the first quarter valued at $294,000. Finally, Shufro Rose & Co. LLC lifted its holdings in shares of Keryx Biopharmaceuticals by 26.1% in the second quarter. Shufro Rose & Co. LLC now owns 91,800 shares of the biopharmaceutical company’s stock valued at $345,000 after buying an additional 19,000 shares during the period. 61.43% of the stock is owned by institutional investors.

About Keryx Biopharmaceuticals

Keryx Biopharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on providing medicines for patients with kidney disease in the United States. It markets its lead product Auryxia (ferric citrate), an orally available, absorbable, iron-based medicine for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis, as well as for the treatment of iron deficiency anemia in adults with CKD not on dialysis.

Featured Story: How to Track your Portfolio in Google Finance

Analyst Recommendations for Keryx Biopharmaceuticals (NASDAQ:KERX)

Receive News & Ratings for Keryx Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keryx Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.